5 stories
Weight loss as a tag covers the practical clinical question — what actually works, how much, in whom, and for how long — across the full peptide pipeline.
The headline data sources: SURMOUNT-5 (tirzepatide vs semaglutide), ACHIEVE-3 (orforglipron in obesity), TRIUMPH (retatrutide), REDEFINE-1 (CagriSema), the STEP series (semaglutide), and the growing real-world evidence literature on what 12-month outcomes look like outside trial conditions. SURMOUNT-5 set the current high-water mark at 21.6% mean weight loss for tirzepatide; retatrutide Phase 2 went above 24%.
Stories here cover the readouts, the discontinuation and weight-regain data, and the head-to-head comparisons. See #obesity for the broader category and #body-composition for muscle-mass and lean-tissue work.
Published the day after Foundayo's FDA approval, a new indirect comparison found oral semaglutide may produce greater weight loss than orforglipron with fewer GI discontinuations.
With one in ten American adults already on GLP-1 drugs, next-generation medications including Foundayo and retatrutide could reach the ~25% of patients who don't respond to current GLP-1 monotherapies.
Eli Lilly's triple GLP-1/GIP/glucagon receptor agonist retatrutide demonstrated up to 28.7% weight loss along with significant knee pain reductions in obesity patients with osteoarthritis. Seven additional Phase 3 trials expected to report throughout 2026.
The ATTAIN-MAINTAIN trial demonstrated that patients switching from injectable semaglutide or tirzepatide to oral orforglipron maintained their weight loss.
New research finds approximately 25% of weight lost persists after GLP-1 discontinuation. Trajectories were similar across semaglutide, liraglutide, and tirzepatide.